Shots:

• The P-III RAP-MD (01-02-03-04) studies involve assessing of Rapastinel (450mg- 225mg) vs PBO as an adjunctive treatment of MDD
• The P-III RAP-MD-04 study demonstrated unmet 1EPs & 2EPs. RAP-MD (01-02-03) studies resulted that Rapastinel was well tolerated with no psychotomimetic side effects
• Rapastinel (IV- qw) is a novel anti-depressant- enhanced NMDAR activity by acting as a partial agonist at the glycine site

Ref: Allergen | Image: Endpoints News